Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
HOME > BUSINESS
BUSINESS
- DSP Posts 46.5 % Rise in April-December Operating Profit Despite Japan Sales Fall
February 5, 2013
- Nesp, Mircera Jostling for Market Shares of Pre-Dialysis CKD Patients
February 5, 2013
- Teijin Pharma Appoints Hiroshi Uno as New President Effective from April 1
February 5, 2013
- 13.9 Bil. in Royalties from Gilenya Help Boost Consolidated Sales for April-December: MTPC
February 5, 2013
- Kyowa Kirin Posts Record Operating Profit for 2012; Sales Up 9% in Pharma Division
February 5, 2013
- Eisai’s Operating Profit Drops 34% in April-December as Aricept Sales Fall
February 4, 2013
- Aricept Fails to Meet Minimum Sales Target in Japan: Eisai
February 4, 2013
- Astellas April-Dec. Earnings: XTANDI Starts Off on Good Note, Could Outstrip Full-Year Target
February 4, 2013
- Kyowa Kirin to Launch 3 In-House Products in Europe and US, Aims for Sales of 358 Billion Yen in 2015: New Midterm Plan
February 4, 2013
- Marketing Ability Could Become Decisive Factor as All DPP-4 Inhibitors Are Likely to Obtain the Same Concurrent-use Indications
February 4, 2013
- Daiichi Sankyo Sees 7.1% Sales Rise in April-December, Cuts Domestic Forecast for Nexium
February 1, 2013
- Chugai Begins Development of Hyperlipidemia Antibody RG7652
February 1, 2013
- Oncology Products Boost Sales, Profits in 2012, but Both Fall Short of Midterm Targets: Chugai
February 1, 2013
- Chugai’s New Midterm Plan Includes No Sales or Profit Targets, Aims for Increased Marketing Productivity
February 1, 2013
- BindRen Approved in Europe for Hyperphosphatemia: MTPC
January 31, 2013
- Chugai Files NDA for Antibody-Drug Conjugate T-DM1 for HER2-Positive Breast Cancer
January 31, 2013
- Higher Dose of Toviaz Further Reduces Urge Urinary Incontinence in Patients with OAB: Pfizer
January 31, 2013
- TS-1 Superior to Gemcitabine in Extending OS of Resected Pancreatic Cancer Patients in PIII Study: Taiho
January 30, 2013
- No New Safety Concerns Found in All-Case PMS of Vectibix: Takeda
January 30, 2013
- “Hybrid” Bioventures Might Help Japanese Pharmas Compete in the Global Market: Prof. Kneller
January 30, 2013
ページ
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…